Cancer Immunology, Immunotherapy

, Volume 56, Issue 9, pp 1323–1334 | Cite as

Role of IL-21 in immune-regulation and tumor immunotherapy

  • Emma di Carlo
  • Daniela de Totero
  • Tiziana Piazza
  • Marina Fabbi
  • Silvano Ferrini
Review

Abstract

IL-21, the most recently discovered member of the IL-2 cytokine family, is an attractive subject for research due to its involvement in experimental models of autoimmunity, its ability to down-regulate IgE production, and its anti-tumor properties. Its interest for cancer immunotherapy stems from its physiological immune-enhancing functions. These include regulation of T, B and NK cell proliferation, survival, differentiation, and effector functions. IL-21’s functional activities partially overlap those of IL-2. Both cytokines display similar structural features and use the common γ-chain receptor and its downstream signaling pathways. Besides its activities on normal lymphoid cells, IL-21 is an in vitro growth factor for myeloma and acute-T cell leukemia cells, whereas it induces the apoptosis of B-CLL (chronic lymphocytic leukemia) cells. These findings indicate that the IL-21/IL-21R system exerts opposite functions in different lymphoid neoplasias, and suggest its employment in B-CLL therapy. Since IL-2, but not IL-21, is specifically required for the development of regulatory T (Treg) cell immune-suppressive functions, IL-21 may be a new tool for cancer immunotherapy. It is, in fact, a powerful anti-tumor agent in a variety of murine experimental tumor models through its activation of specific or innate immune responses against neoplastic cells. The preliminary data from phase-I clinical studies suggest that the use of IL-21 is feasible and may result in immune-enhancing effects.

Keywords

Interleukin-21 Immune-regulation Lymphoid neoplasia Tumor immunotherapy 

References

  1. 1.
    Alves NL, Arosa FA, van Lier RA (2005) IL-21 sustains CD28 expression on IL-15-activated human naive CD8+ T cells. J Immunol 175:755–762PubMedGoogle Scholar
  2. 2.
    Asao H, Okuyama C, Kumaki S, Ishii N, Tsuchiya S, Foster D, Sugamura K (2001) Cutting edge: the common gamma-chain is an indispensable subunit of the IL-21 receptor complex. J Immunol 167:1–5PubMedGoogle Scholar
  3. 3.
    Baratelli F, Lin Y, Zhu L, Yang SC, Heuze-Vourc’h N, Zeng G, Reckamp K, Dohadwala M, Sharma S, Dubinett SM (2005) Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4+ T cells. J Immunol 175:1483–1490PubMedGoogle Scholar
  4. 4.
    Bayer AL, Yu A, Adeegbe D, Malek TR (2005) Essential role for interleukin-2 for CD4(+)CD25(+) T regulatory cell development during the neonatal period. J Exp Med 201:769–777PubMedCrossRefGoogle Scholar
  5. 5.
    Bolesta E, Kowalczyk A, Wierzbicki A, Eppolito C, Kaneko Y, Takiguchi M, Stamatatos L, Shrikant PA, Kozbor D (2006) Increased level and longevity of protective immune responses induced by DNA vaccine expressing the HIV-1 Env glycoprotein when combined with IL-21 and IL-15 gene delivery. J Immunol 177:177–191PubMedGoogle Scholar
  6. 6.
    Bracci L, Moschella F, Sestili P, La Sorsa V, Valentini M, Canini I, Baccarini S, Maccari S, Ramoni C, Belardelli F, Proietti E (2007) Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-Cell and T-Cell homeostatic proliferation, and specific tumor infiltration. Clin Cancer Res 13:644–653PubMedCrossRefGoogle Scholar
  7. 7.
    Brady J, Hayakawa Y, Smyth MJ, Nutt SL (2004) IL-21 induces the functional maturation of murine NK cells. J Immunol 172:2048–2058PubMedGoogle Scholar
  8. 8.
    Brandt K, Bulfone-Paus S, Foster DC, Ruckert R (2003) Interleukin-21 inhibits dendritic cell activation and maturation. Blood 102:4090–4098PubMedCrossRefGoogle Scholar
  9. 9.
    Brenne AT, Ro TB, Waage A, Sundan A, Borset M, Hjorth-Hansen H (2002) Interleukin-21 is a growth and survival factor for human myeloma cells. Blood 99:3756–3762PubMedCrossRefGoogle Scholar
  10. 10.
    Burgess SJ, Marusina AI, Pathmanathan I, Borrego F, Coligan JE (2006) IL-21 down-regulates NKG2D/DAP10 expression on human NK and CD8+ T cells. J Immunol 176:1490–1497PubMedGoogle Scholar
  11. 11.
    Cappuccio A, Elishmereni M, Agur Z (2006) Cancer immunotherapy by interleukin-21: potential treatment strategies evaluated in a mathematical model. Cancer Res 66:7293–7300PubMedCrossRefGoogle Scholar
  12. 12.
    Caruso R, Fina D, Peluso I, Stolfi C, Fantini MC, Gioia V, Caprioli F, Del Vecchio Blanco G, Paoluzi OA, Macdonald TT, Pallone F, Monteleone G (2007) A functional role for interleukin-21 in promoting the synthesis of the T-Cell Chemoattractant, MIP-3alpha, by gut epithelial cells. Gastroenterology 132:166–175PubMedCrossRefGoogle Scholar
  13. 13.
    Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, McGrady G, Wahl SM (2003) Conversion of peripheral CD4 + CD25- naive T cells to CD4 + CD25 + regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 198:1875–1886PubMedCrossRefGoogle Scholar
  14. 14.
    Comes A, Rosso O, Orengo AM, Di Carlo E, Sorrentino C, Meazza R, Piazza T, Valzasina B, Nanni P, Colombo MP, Ferrini S (2006) CD25 + regulatory T cell depletion augments immunotherapy of micrometastases by an IL-21-secreting cellular vaccine. J Immunol 176:1750–1758PubMedGoogle Scholar
  15. 15.
    Curti BD (2006) Immunomodulatory and antitumor effects of interleukin-21 in patients with renal cell carcinoma (review). Expert Rev Anticancer Ther 6:905–909PubMedCrossRefGoogle Scholar
  16. 16.
    de Totero D, Francia di Celle P, Cignetti A, Foa R (1995) The IL-2 receptor complex: expression and function on normal and leukemic B cells (review). Leukemia 9:1425–1431PubMedGoogle Scholar
  17. 17.
    de Totero D, Meazza R, Zupo S, Cutrona G, Matis S, Colombo M, Balleari E, Pierri I, Fabbi M, Capaia M, Azzarone B, Gobbi M, Ferrarini M, Ferrini S (2006) Interleukin-21 receptor (IL-21R) is up-regulated by CD40 triggering and mediates proapoptotic signals in chronic lymphocytic leukemia B cells. Blood 107:3708–3715PubMedCrossRefGoogle Scholar
  18. 18.
    Di Carlo E, Comes A, Orengo AM, Rosso O, Meazza R, Musiani P, Colombo MP, Ferrini S (2004) IL-21 induces tumor rejection by specific CTL and IFN-gamma-dependent CXC chemokines in syngeneic mice. J Immunol 172:1540–1547PubMedGoogle Scholar
  19. 19.
    Dicker F, Kater AP, Fukuda T, Kipps TJ (2005) Fas-ligand (CD178) and TRAIL synergistically induce apoptosis of CD40-activated chronic lymphocytic leukemia B cells. Blood 105:3193–3198PubMedCrossRefGoogle Scholar
  20. 20.
    Distler JH, Jungel A, Kowal-Bielecka O, Michel BA, Gay RE, Sprott H, Matucci-Cerinic M, Chilla M, Reich K, Kalden JR, Muller-Ladner U, Lorenz HM, Gay S, Distler O (2005) Expression of interleukin-21 receptor in epidermis from patients with systemic sclerosis. Arthritis 52:856–864CrossRefGoogle Scholar
  21. 21.
    Ferrone CR, Perales MA, Goldberg SM, Somberg CJ, Hirschhorn-Cymerman D, Gregor PD, Turk MJ, Ramirez-Montagut T, Gold JS, Houghton AN, Wolchok JD (2006) Adjuvanticity of plasmid DNA encoding cytokines fused to immunoglobulin Fc domains. Clin Cancer Res 12:5511–5519PubMedCrossRefGoogle Scholar
  22. 22.
    Frohlich A, Marsland BJ, Sonderegger I, Kurrer M, Hodge MR, Harris NL, Kopf M (2007) IL-21 receptor signaling is integral to the development of Th2 effector responses in vivo. Blood 109:2023–2031PubMedCrossRefGoogle Scholar
  23. 23.
    Furukawa J, Hara I, Nagai H, Yao A, Oniki S, Fujisawa M (2006) Interleukin-21 gene transfection into mouse bladder cancer cells results in tumor rejection through the cytotoxic T lymphocyte response. J Urol 176:1198–1203PubMedCrossRefGoogle Scholar
  24. 24.
    Gagnon J, Ramanathan S, Leblanc C, Ilangumaran S (2007) Regulation of IL-21 signaling by suppressor of cytokine signaling-1 (SOCS1) in CD8(+) T lymphocytes. Cell Signal 19:806–816PubMedCrossRefGoogle Scholar
  25. 25.
    Good KL, Bryant VL, Tangye SG (2006) Kinetics of human B cell behavior and amplification of proliferative responses following stimulation with IL-21. J Immunol 177:5236–5247PubMedGoogle Scholar
  26. 26.
    Habib T, Senadheera S, Weinberg K, Kaushansky K (2002) The common gamma chain (gamma c) is a required signaling component of the IL-21 receptor and supports IL-21-induced cell proliferation via JAK3. Biochemistry 41:8725–8731PubMedCrossRefGoogle Scholar
  27. 27.
    Harada M, Magara-Koyanagi K, Watarai H, Nagata Y, Ishii Y, Kojo S, Horiguchi S, Okamoto Y, Nakayama T, Suzuki N, Yeh WC, Akira S, Kitamura H, Ohara O, Seino K, Taniguchi M (2006) IL-21-induced Bepsilon cell apoptosis mediated by natural killer T cells suppresses IgE responses. J Exp Med 203:2929–2937PubMedCrossRefGoogle Scholar
  28. 28.
    He H, Wisner P, Yang G, Hu HM, Haley D, Miller W, O’hara A, Alvord WG, Clegg CH, Fox BA, Urba WJ, Walker EB (2006) Combined IL-21 and low-dose IL-2 therapy induces anti-tumor immunity and long-term curative effects in a murine melanoma tumor model. J Transl Med 4:24PubMedCrossRefGoogle Scholar
  29. 29.
    Herber D, Brown TP, Liang S, Young DA, Collins M, Dunussi-Joannopoulos K (2007) IL-21 has a pathogenic role in a lupus-prone mouse model and its blockade with IL-21R.Fc reduces disease progression. J Immunol 178:3822–3830PubMedGoogle Scholar
  30. 30.
    Jahrsdorfer B, Blackwell SE, Wooldridge JE, Huang J, Andreski MW, Jacobus LS, Taylor CM, Weiner GJ (2006) B-chronic lymphocytic leukemia cells and other B cells can produce granzyme B and gain cytotoxic potential after interleukin-21-based activation. Blood 108:2712–2719PubMedCrossRefGoogle Scholar
  31. 31.
    Jin H, Carrio R, Yu A, Malek TR (2004) Distinct activation signals determine whether IL-21 induces B cell costimulation, growth arrest, or Bim-dependent apoptosis. J Immunol 173:657–665PubMedGoogle Scholar
  32. 32.
    Jungel A, Distler JH, Kurowska-Stolarska M, Seemayer CA, Seibl R, Forster A, Michel BA, Gay RE, Emmrich F, Gay S, Distler O (2004) Expression of interleukin-21 receptor, but not interleukin-21, in synovial fibroblasts and synovial macrophages of patients with rheumatoid arthritis. Arthritis Rheum 50:1468–1476PubMedCrossRefGoogle Scholar
  33. 33.
    Kasaian MT, Whitters MJ, Carter LL, Lowe LD, Jussif JM, Deng B, Johnson KA, Witek JS, Senices M, Konz RF, Wurster AL, Donaldson DD, Collins M, Young DA, Grusby MJ (2002) IL-21 limits NK cell responses and promotes antigen-specific T cell activation: a mediator of the transition from innate to adaptive immunity. Immunity 16:559–569PubMedCrossRefGoogle Scholar
  34. 34.
    Kim HP, Korn LL, Gamero AM, Leonard WJ (2005) Calcium-dependent activation of interleukin-21 gene expression in T cells. J Biol Chem 280:25291–25297PubMedCrossRefGoogle Scholar
  35. 35.
    King C, Ilic A, Koelsch K, Sarvetnick N (2004) Homeostatic expansion of T cells during immune insufficiency generates autoimmunity. Cell 117:265–277PubMedCrossRefGoogle Scholar
  36. 36.
    Kishida T, Asada H, Itokawa Y, Cui FD, Shin-Ya M, Gojo S, Yasutomi K, Ueda Y, Yamagishi H, Imanishi J, Mazda O (2003) Interleukin (IL)-21 and IL-15 genetic transfer synergistically augments therapeutic antitumor immunity and promotes regression of metastatic lymphoma. Mol Ther 8:552–558PubMedCrossRefGoogle Scholar
  37. 37.
    Ko K, Yamazaki S, Nakamura K, Nishioka T, Hirota K, Yamaguchi T, Shimizu J, Nomura T, Chiba T, Sakaguchi S (2005) Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3 + CD25 + CD4 + regulatory T cells. J Exp Med 202:885–891PubMedCrossRefGoogle Scholar
  38. 38.
    Konforte D, Paige CJ (2006) Identification of cellular intermediates and molecular pathways induced by IL-21 in human B cells. J Immunol 177:8381–8392PubMedGoogle Scholar
  39. 39.
    Kovanen PE, Leonard WJ (2004) Cytokines and immunodeficiency diseases: critical roles of the gamma(c)-dependent cytokines interleukins 2, 4, 7, 9, 15, and 21, and their signaling pathways (review). Immunol Rev 202:67–83PubMedCrossRefGoogle Scholar
  40. 40.
    Leonard WJ, Spolski R (2005) Interleukin-21: a modulator of lymphoid proliferation, apoptosis and differentiation (review). Nat Rev Immunol 5:688–698PubMedCrossRefGoogle Scholar
  41. 41.
    Li Y, Bleakley M, Yee C (2005) IL-21 influences the frequency, phenotype, and affinity of the antigen-specific CD8 T cell response. J Immunol 175:2261–2269PubMedGoogle Scholar
  42. 42.
    Li J, Shen W, Kong K, Liu Z (2006) Interleukin-21 induces T-cell activation and proinflammatory cytokine secretion in rheumatoid arthritis. Scand J Immunol 64:515–522PubMedCrossRefGoogle Scholar
  43. 43.
    Ma HL, Whitters MJ, Konz RF, Senices M, Young DA, Grusby MJ, Collins M, Dunussi-Joannopoulos K (2003) IL-21 activates both innate and adaptive immunity to generate potent antitumor responses that require perforin but are independent of IFN-gamma. J Immunol 171:608–615PubMedGoogle Scholar
  44. 44.
    Malek TR, Bayer AL (2004) Tolerance, not immunity, crucially depends on IL-2 (review). Nat Rev Immunol 4:665–674PubMedCrossRefGoogle Scholar
  45. 45.
    Mehta DS, Wurster AL, Whitters MJ, Young DA, Collins M, Grusby MJ (2003) IL-21 induces the apoptosis of resting and activated primary B cells. J Immunol 170:4111–4118PubMedGoogle Scholar
  46. 46.
    Mehta DS, Wurster AL, Weinmann AS, Grusby MJ (2005) NFATc2 and T-bet contribute to T-helper-cell-subset-specific regulation of IL-21 expression. Proc Natl Acad Sci USA 102:2016–2021PubMedCrossRefGoogle Scholar
  47. 47.
    Monteleone G, Monteleone I, Fina D, Vavassori P, Del Vecchio Blanco G, Caruso R, Tersigni R, Alessandroni L, Biancone L, Naccari GC, MacDonald TT, Pallone F (2005) Interleukin-21 enhances T-helper cell type I signaling and interferon-gamma production in Crohn’s disease. Gastroenterology 128:687–694PubMedCrossRefGoogle Scholar
  48. 48.
    Moroz A, Eppolito C, Li Q, Tao J, Clegg CH, Shrikant PA (2004) IL-21 enhances and sustains CD8+ T cell responses to achieve durable tumor immunity: comparative evaluation of IL-2, IL-15, and IL-21. J Immunol 173:900–909PubMedGoogle Scholar
  49. 49.
    Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, Nakayama E (1999) Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res 59:3128–3133PubMedGoogle Scholar
  50. 50.
    Ozaki K, Hishiya A, Hatanaka K, Nakajima H, Wang G, Hwu P, Kitamura T, Ozawa K, Leonard WJ, Nosaka T (2006) Overexpression of interleukin 21 induces expansion of hematopoietic progenitor cells. Int J Hematol 84:224–230PubMedCrossRefGoogle Scholar
  51. 51.
    Ozaki K, Kikly K, Michalovich D, Young PR, Leonard WJ (2000) Cloning of a type I cytokine receptor most related to the IL-2 receptor beta chain. Proc Natl Acad Sci USA 97:11439–11444PubMedCrossRefGoogle Scholar
  52. 52.
    Ozaki K, Leonard WJ (2002) Cytokine and cytokine receptor pleiotropy and redundancy (review). J Biol Chem 277:29355–29358PubMedCrossRefGoogle Scholar
  53. 53.
    Ozaki K, Spolski R, Ettinger R, Kim HP, Wang G, Qi CF, Hwu P, Shaffer DJ, Akilesh S, Roopenian DC, Morse HC 3rd, Lipsky PE, Leonard WJ (2004) Regulation of B cell differentiation and plasma cell generation by IL-21, a novel inducer of Blimp-1 and Bcl-6. J Immunol 173:5361–5371PubMedGoogle Scholar
  54. 54.
    Ozaki K, Spolski R, Feng CG, Qi CF, Cheng J, Sher A, Morse HC 3rd, Liu C, Schwartzberg PL, Leonard WJ (2002) A critical role for IL-21 in regulating immunoglobulin production. Science 298:1630–1634PubMedCrossRefGoogle Scholar
  55. 55.
    Parmiani G, Colombo MP, Melani C, Arienti F (1997) Cytokine gene transduction in the immunotherapy of cancer (review). Adv Pharmacol 40:259–307PubMedCrossRefGoogle Scholar
  56. 56.
    Parrish-Novak J, Dillon SR, Nelson A, Hammond A, Sprecher C, Gross JA, Johnston J, Madden K, Xu W, West J, Schrader S, Burkhead S, Heipel M, Brandt C, Kuijper JL, Kramer J, Conklin D, Presnell SR, Berry J, Shiota F, Bort S, Hambly K, Mudri S, Clegg C, Moore M, Grant FJ, Lofton-Day C, Gilbert T, Rayond F, Ching A, Yao L, Smith D, Webster P, Whitmore T, Maurer M, Kaushansky K, Holly RD, Foster D (2000) Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 408:57–63PubMedCrossRefGoogle Scholar
  57. 57.
    Peluso I, Fantini MC, Fina D, Caruso R, Boirivant M, Macdonald TT, Pallone F, Monteleone G (2007) IL-21 counteracts the regulatory T cell-mediated suppression of human CD4 + T lymphocytes. J Immunol 178:732–9PubMedGoogle Scholar
  58. 58.
    Pelletier M, Bouchard A, Girard D (2004) In vivo and in vitro roles of IL-21 in inflammation. J Immunol 173:7521–7530PubMedGoogle Scholar
  59. 59.
    Pesce J, Kaviratne M, Ramalingam TR, Thompson RW, Urban JF Jr, Cheever AW, Young DA, Collins M, Grusby MJ, Wynn TA (2006) The IL-21 receptor augments Th2 effector function and alternative macrophage activation. J Clin Invest 116:2044–2055PubMedCrossRefGoogle Scholar
  60. 60.
    Refaeli Y, Van Parijs L, London CA, Tschopp J, Abbas AK (1998) Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis. Immunity 8:615–623PubMedCrossRefGoogle Scholar
  61. 61.
    Roda JM, Parihar R, Lehman A, Mani A, Tridandapani S, Carson WE 3rd (2006) Interleukin-21 enhances NK cell activation in response to antibody-coated targets. J Immunol 177:120–129PubMedGoogle Scholar
  62. 62.
    Sakaguchi S, Ono M, Setoguchi R, Yagi H, Hori S, Fehervari Z, Shimizu J, Takahashi T, Nomura T (2006) Foxp3 + CD25 + CD4 + natural regulatory T cells in dominant self-tolerance and autoimmune disease (review). Immunol Rev 212:8–27PubMedCrossRefGoogle Scholar
  63. 63.
    Sadlack B, Merz H, Schorle H, Schimpl A, Feller AC, Horak I (1993) Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 75:253–261PubMedCrossRefGoogle Scholar
  64. 64.
    Shan B, Yu L, Shimozato O, Li Q, Tagawa M (2004) Expression of interleukin-21 and -23 in human esophageal tumors produced antitumor effects in nude mice. Anticancer Res 24:79–82PubMedGoogle Scholar
  65. 65.
    Sivori S, Cantoni C, Parolini S, Marcenaro E, Conte R, Moretta L, Moretta A (2003) IL-21 induces both rapid maturation of human CD34 + cell precursors towards NK cells and acquisition of surface killer Ig-like receptors. Eur J Immunol 33:3439–47PubMedCrossRefGoogle Scholar
  66. 66.
    Smyth MJ, Hayakawa Y, Cretney E, Zerafa N, Sivakumar P, Yagita H, Takeda K (2006) IL-21 enhances tumor-specific CTL induction by anti-DR5 antibody therapy. J Immunol 176:6347–6355PubMedGoogle Scholar
  67. 67.
    Smyth MJ, Wallace ME, Nutt SL, Yagita H, Godfrey DI, Hayakawa Y (2005) Sequential activation of NKT cells and NK cells provides effective innate immunotherapy of cancer. J Exp Med 201:1973–1985PubMedCrossRefGoogle Scholar
  68. 68.
    Sondergaard H, Frederiksen KS, Thygesen P, Galsgaard ED, Skak K, Kristjansen PE, Odum N, Kragh M (2007) Interleukin 21 therapy increases the density of tumor infiltrating CD8(+) T cells and inhibits the growth of syngeneic tumors. Cancer Immunol Immunother (Epub ahead of print)Google Scholar
  69. 69.
    Stephanou A, Latchman DS (2003) STAT-1: a novel regulator of apoptosis (review). Int J Exp Pathol 84:239–244PubMedCrossRefGoogle Scholar
  70. 70.
    Strengell M, Lehtonen A, Matikainen S, Julkunen I (2006) IL-21 enhances SOCS gene expression and inhibits LPS-induced cytokine production in human monocyte-derived dendritic cells. J Leukoc Biol 79:1279–1285PubMedCrossRefGoogle Scholar
  71. 71.
    Strengell M, Sareneva T, Foster D, Julkunen I, Matikainen S (2002) IL-21 up-regulates the expression of genes associated with innate immunity and Th1 response. J Immunol 169:3600–3605PubMedGoogle Scholar
  72. 72.
    Suto A, Nakajima H, Hirose K, Suzuki K, Kagami S, Seto Y, Hoshimoto A, Saito Y, Foster DC, Iwamoto I (2002) Interleukin 21 prevents antigen-induced IgE production by inhibiting germ line C(epsilon) transcription of IL-4-stimulated B cells. Blood 100:4565–4573PubMedCrossRefGoogle Scholar
  73. 73.
    Suto A, Wurster AL, Reiner SL, Grusby MJ (2006) IL-21 inhibits IFN-gamma production in developing Th1 cells through the repression of Eomesodermin expression. J Immunol 177:3721–3727PubMedGoogle Scholar
  74. 74.
    Takaki R, Hayakawa Y, Nelson A, Sivakumar PV, Hughes S, Smyth MJ, Lanier LL (2005) IL-21 enhances tumor rejection through a NKG2D-dependent mechanism. J Immunol 175:2167–2173PubMedGoogle Scholar
  75. 75.
    Toomey JA, Gays F, Foster D, Brooks CG (2003) Cytokine requirements for the growth and development of mouse NK cells in vitro. J Leukoc Biol 74:233–242PubMedCrossRefGoogle Scholar
  76. 76.
    Trentin L, Cerutti A, Zambello R, Sancretta R, Tassinari C, Facco M, Adami F, Rodeghiero F, Agostini C, Semenzato G (1996) Interleukin-15 promotes the growth of leukemic cells of patients with B-cell chronic lymphoproliferative disorders. Blood 87:3327–3335PubMedGoogle Scholar
  77. 77.
    Ueda M, Imada K, Imura A, Koga H, Hishizawa M, Uchiyama T (2005) Expression of functional interleukin-21 receptor on adult T-cell leukaemia cells. Br J Haematol 128:169–176PubMedCrossRefGoogle Scholar
  78. 78.
    Ugai S, Shimozato O, Kawamura K, Wang YQ, Yamaguchi T, Saisho H, Sakiyama S, Tagawa M (2003) Expression of the interleukin-21 gene in murine colon carcinoma cells generates systemic immunity in the inoculated hosts. Cancer Gene Ther 10:187–192PubMedCrossRefGoogle Scholar
  79. 79.
    Ugai S, Shimozato O, Yu L, Wang YQ, Kawamura K, Yamamoto H, Yamaguchi T, Saisho H, Sakiyama S, Tagawa M (2003) Transduction of the IL-21 and IL-23 genes in human pancreatic carcinoma cells produces natural killer cell-dependent and -independent antitumor effects. Cancer Gene Ther 10:771–778PubMedCrossRefGoogle Scholar
  80. 80.
    van Elsas A, Sutmuller RP, Hurwitz AA, Ziskin J, Villasenor J, Medema JP, Overwijk WW, Restifo NP, Melief CJ, Offringa R, Allison JP (2001) Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy. J Exp Med 194:481–489PubMedCrossRefGoogle Scholar
  81. 81.
    Valzasina B, Guiducci C, Dislich H, Killeen N, Weinberg AD, Colombo MP (2005) Triggering of OX40 (CD134) on CD4(+)CD25+ T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR. Blood 105:2845–2851PubMedCrossRefGoogle Scholar
  82. 82.
    Valzasina B, Piconese S, Guiducci C, Colombo MP (2006) Tumor-induced expansion of regulatory T cells by conversion of CD4 + CD25- lymphocytes is thymus and proliferation independent. Cancer Res 66:4488–4495PubMedCrossRefGoogle Scholar
  83. 83.
    van Leeuwen EM, van Buul JD, Remmerswaal EB, Hordijk PL, ten Berge IJ, van Lier RA (2005) Functional re-expression of CCR7 on CMV-specific CD8+ T cells upon antigenic stimulation. Int Immunol 17:713–719PubMedCrossRefGoogle Scholar
  84. 84.
    Vollmer TL, Liu R, Price M, Rhodes S, La Cava A, Shi FD (2005) Differential effects of IL-21 during initiation and progression of autoimmunity against neuroantigen. J Immunol 174:2696–2701PubMedGoogle Scholar
  85. 85.
    Vosshenrich CA, Ranson T, Samson SI, Corcuff E, Colucci F, Rosmaraki EE, Di Santo JP (2005) Roles for common cytokine receptor gamma-chain-dependent cytokines in the generation, differentiation, and maturation of NK cell precursors and peripheral NK cells in vivo. J Immunol 174:1213–1221PubMedGoogle Scholar
  86. 86.
    Wang G, Tschoi M, Spolski R, Lou Y, Ozaki K, Feng C, Kim G, Leonard WJ, Hwu P (2003) In vivo antitumor activity of interleukin 21 mediated by natural killer cells. Cancer Res 63:9016–9022PubMedGoogle Scholar
  87. 87.
    Willerford DM, Chen J, Ferry JA, Davidson L, Ma A, Alt FW (1995) Interleukin-2 receptor alpha chain regulates the size and content of the peripheral lymphoid compartment. Immunity 3:521–530PubMedCrossRefGoogle Scholar
  88. 88.
    White L, Krishnan S, Strbo N, Liu H, Kolber MA, Lichtenheld MG, Pahwa R, Pahwa S (2007) Differential effects of IL-21 and IL-15 on perforin expression, lysosomal degranulation and proliferation in CD8 T cells of patients infected with Human Immunodeficiency Virus-1 (HIV). Blood 27 December 2006 (Epub ahead of print)Google Scholar
  89. 89.
    Wurster AL, Rodgers VL, Satoskar AR, Whitters MJ, Young DA, Collins M, Grusby MJ (2002) Interleukin 21 is a T helper (Th) cell 2 cytokine that specifically inhibits the differentiation of naive Th cells into interferon gamma-producing Th1 cells. J Exp Med 196:969–977PubMedCrossRefGoogle Scholar
  90. 90.
    Yamaoka K, Min B, Zhou YJ, Paul WE, O’shea JJ (2005) Jak3 negatively regulates dendritic-cell cytokine production and survival. Blood 106:3227–3233PubMedCrossRefGoogle Scholar
  91. 91.
    Zeng R, Spolski R, Casas E, Zhu W, Levy DE, Leonard WJ (2007) The molecular basis of IL-21-mediated proliferation. Blood 18 January 2007 (Epub ahead of print)Google Scholar
  92. 92.
    Zeng R, Spolski R, Finkelstein SE, Oh S, Kovanen PE, Hinrichs CS, Pise-Masison CA, Radonovich MF, Brady JN, Restifo NP, Berzofsky JA, Leonard WJ (2005) Synergy of IL-21 and IL-15 in regulating CD8 + T cell expansion and function. J Exp Med 201:139–148PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Emma di Carlo
    • 1
  • Daniela de Totero
    • 2
  • Tiziana Piazza
    • 2
  • Marina Fabbi
    • 2
  • Silvano Ferrini
    • 2
  1. 1.Dipartimento di Oncologia e Neuroscienze, Sezione di Patologia Chirurgica, and Ce.S.I. Aging Research CenterFondazione Universitaria “G. d’Annunzio”ChietiItaly
  2. 2.Immunotherapy UnitIstituto Nazionale per la Ricerca sul CancroGenoaItaly

Personalised recommendations